BiotechTube

CNSA-001 + Placebo

Phase 2Completed
0 watching 0 views this week⚡ Active
49
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Gastroparesis

Conditions

Gastroparesis

Trial Timeline

Feb 27, 2019 → Oct 8, 2019

NCT ID
NCT03712124

About CNSA-001 + Placebo

CNSA-001 + Placebo is a phase 2 stage product being developed by PTC Therapeutics for Gastroparesis. The current trial status is completed. This product is registered under clinical trial identifier NCT03712124. Target conditions include Gastroparesis.

Hype Score Breakdown

Clinical
17
Activity
12
Company
7
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT03712124Phase 2Completed

Competing Products

19 competing products in Gastroparesis

See all competitors
ProductCompanyStageHype Score
tadalafil + tadalafil + placeboEli LillyPhase 2
52
GranisetronKyowa KirinPhase 2
52
tadalafilEli LillyApproved
85
Mosapride + domperidoneSumitomo PharmaApproved
85
Cisapride + PlaceboJohnson & JohnsonApproved
85
Cisapride + PlaceboJohnson & JohnsonApproved
85
Naloxegol 25 MG Oral Tablet [Movantik] + Placebo Oral TabletAstraZenecaPhase 2
52
Sitagliptin + PlaceboMerckPhase 1
33
TegaserodNovartisApproved
85
Reglan ODTUCBPre-clinical
20
Hemin + AlbuminRecordatiPhase 2
49
Immediate-release omeprazole + Delayed-release omeprazoleBausch HealthApproved
80
Velusetrag + PlaceboTheravance BiopharmaPhase 2
47
velusetrag dose 1 + velusetrag dose 2 + velusetrag dose 3 + placeboTheravance BiopharmaPhase 2
47
IW-9179 + Matching PlaceboIronwood PharmaceuticalsPhase 2
44
VLY-686 (Tradipitant)Vanda PharmaceuticalsPhase 2
44
TradipitantVanda PharmaceuticalsPhase 3
69
TradipitantVanda PharmaceuticalsPre-clinical
15
Tradipitant + Placebo + Open Label TradipitantVanda PharmaceuticalsPhase 3
69

Other Products from PTC Therapeutics

Ataluren + PlaceboPhase 3
74
AtalurenPhase 3
74
Ataluren (PTC124®) + PlaceboPhase 3
74
Ataluren + PlaceboPhase 3
74
DeflazacortPhase 3
74